Related Experiment Video

Updated: May 16, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

8-Chloroadenosine 3',5'-monophosphate induces cell cycle arrest and apoptosis in multiple myeloma cells through

Yi-Min Cheng1, Qi Zhu, Yi-Yun Yao

  • 1Department of Hematology, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China.

Oncology Letters
|December 11, 2012
PubMed

Insights

8-chloroadenosine 3

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • Multiple myeloma (MM) is a hematological malignancy.
  • Understanding novel therapeutic targets is crucial for MM treatment.
  • Cyclic adenosine monophosphate (cAMP) signaling pathways are implicated in cancer progression.

Purpose of the Study:

  • To elucidate the molecular mechanisms by which 8-chloroadenosine 3',5'-monophosphate (8-Cl-cAMP) inhibits multiple myeloma cell growth.
  • To investigate the role of 8-Cl-cAMP in inducing apoptosis in multiple myeloma cells.

Main Methods:

  • Utilized two multiple myeloma cell lines (RPMI-8226 and U266).
  • Assessed cell viability, apoptosis induction, and mitochondrial transmembrane potential.
  • Quantified expression levels of cell cycle regulators (Cdk2, cyclin E, p27, c-myc) and p38 mitogen-activated protein kinase (MAPK).
  • Employed a p38 MAPK inhibitor and p27 knockdown for mechanistic studies.

Main Results:

  • 8-Cl-cAMP treatment increased apoptosis in a dose- and time-dependent manner.
  • Mitochondrial transmembrane potential collapse was observed, indicating apoptosis.
  • 8-Cl-cAMP induced p38 MAPK phosphorylation and increased p27 expression while decreasing c-myc.
  • Inhibition of p38 MAPK or knockdown of p27 partially reversed the pro-apoptotic effects of 8-Cl-cAMP.

Conclusions:

  • 8-Cl-cAMP induces cell cycle arrest and apoptosis in multiple myeloma cells via a p27-dependent pathway.
  • The p38 MAPK pathway is involved in mediating the effects of 8-Cl-cAMP.
  • cAMP-modulating agents show potential as a therapeutic strategy for multiple myeloma.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...